Summit Therapeutics sinks 16% after the FDA rejects

Summit Therapeutics' stock fell 16.44% to $11.82 on Nov. 16, 2026, after the FDA rejected ivonescimab due to insufficient survival data. The company reported $613 million in net losses for the first nine months of 2026, with no product revenue. Analysts noted the rejection could impact Summit's larger lung cancer program.

Original reporting
Published Nov 17, 2026, 12:39 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 1:37 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$SMMT
Bearish
high confidence
Mentioned
$SMMT
Relevance
9/10
AlphAI data visualization · based on quantisnow.com
Decision brief

The 30-second read

$SMMTBearishHigh
01

Why it matters

The FDA complete response letter closes the nearest path to a U.S. launch and signals that tumor control without statistically significant overall survival is not enough, potentially affecting both the specific indication and investor expectations for the broader first-line program.

02

Market read

A same-session regulatory denial drove a large single-day equity repricing, with the market focusing on survival-endpoint gating and implications for future resubmission or first-line development.

03

What to watch

The article says Summit has not disclosed how the FDA weighed later cuts or other indications, so the market may be missing details that could support a resubmission strategy.

Relevance 9/10Novelty 9/10Timing: reaction in the next regular session after the Nov. 15 complete response letter

Background

Summit’s ivonescimab application for EGFR-mutated, non-squamous non-small cell lung cancer was reviewed under the HARMONi trial, where progression-free survival was met but overall survival was not statistically significant in the primary analysis.

Company-level read

Ticker impact

$SMMTBearishHigh confidence
Context

Summit Therapeutics shares plunged after the FDA issued a complete response letter rejecting ivonescimab for lung cancer due to lack of statistically significant overall survival.

Expected impact

Likely further downside or high volatility as the market reprices the probability/timing of any U.S. approval and the broader first-line lung cancer program efficacy bar.

Evidence & confidence

The article states the FDA concluded substantial evidence of effectiveness was not established without statistically significant overall survival improvement, and the stock fell about 16% on heavy volume the next session.

Market effects

Raises the bar for oncology immunotherapy/targeted combinations where progression-free survival alone is insufficient for FDA acceptance.

US biotech sentiment likely pressured, with healthcare ETFs and peers down modestly on the same day.

May affect global EGFR-mutated lung cancer development strategies if survival endpoints remain the key gating factor across regions.

Counterpoint

Investors may be over-discounting the FDA’s interpretation, since the article notes later analyses and an Akeso-run China study showed statistically significant overall survival.

Key entities

  • Summit Therapeutics

    US-listed biotech whose ivonescimab FDA review resulted in a complete response letter tied to overall survival evidence.

  • FDA

    Issued the complete response letter, stating substantial evidence of effectiveness was not established without statistically significant overall survival improvement.

  • ivonescimab

    Summit’s only drug in the article, rejected by the FDA for the described lung cancer indication based on survival endpoint requirements.

  • HARMONi trial

    Trial whose primary overall survival analysis missed statistical significance, driving the FDA’s effectiveness conclusion.

Related articles

$CGONMed

Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection

Biotech stocks moved amid clinical and regulatory news. CG Oncology's bladder cancer drug met its primary endpoint, reducing recurrence risk by 68%. Lexeo's gene therapy showed promising interim data. Summit Therapeutics' lung cancer drug received an FDA rejection, and Aclaris' atopic dermatitis treatment missed Phase 2 goals. The S&P 500 and Nasdaq fell 1.92% and 2.49%, respectively, according to CNBC.

$SMMTHighAI 9/10

FDA Declines Approval of China-Developed Lung Cancer Drug After Survival Goal Missed

The FDA declined to approve Akeso's lung cancer drug ivonescimab, developed with Summit Therapeutics, due to insufficient evidence of improved survival in trials. The drug delayed cancer progression but did not meet statistical survival requirements. Summit plans further trials, and Akeso retains rights in China. AstraZeneca invested $2B in Summit for ivonescimab's development.

$SMMTHighAI 9/10

Summit Therapeutics Sinks on FDA Rejection

Summit Therapeutics (SMMT) shares fell 16.5% after the FDA rejected its lung cancer drug ivonescimab, citing insufficient evidence of overall survival benefit. The company plans to continue development, but no resubmission timeline was provided. Summit's stock closed at $11.82, its lowest since August. The FDA's decision follows positive progression-free survival results but insufficient overall survival data.

$MDCXMed

Small cap wrap: Phunware, Trust Stamp, Medicus Pharma, TNR

TNR Gold (TSX-V:TNR, OTC:TRRXF) agreed to a $122M acquisition by Altius Minerals at a 60% premium. Grey Matters Health (CSE:GREY, OTCQB:AGNPD) gained Medicare/Medicaid accreditation. Snail Inc (NASDAQ:SNAL) received a positive analyst note after Q3 revenue growth. Summit Therapeutics (NASDAQ:SMMT) shares fell 12.69% after FDA rejection. Citi initiated coverage of Amaroq Minerals (AIM:AMRQ, TSX-V:AMRQ) with a 'buy' rating. BioVie (NASDAQ:BIVI, NASDAQ:BIVIW) presented Long COVID trial findings.

$SMMTMedAI 8/10

2 Cancer-Drug Developers Seeing Unusual Options Volume

Summit Therapeutics (SMMT) fell 15% to $12.02 after the FDA declined to approve its lung cancer drug, requesting more survival data. Citi cut its price target to $42. CG Oncology (CGON) rose 12.5% to $83.70 after its bladder cancer treatment met trial goals, reducing recurrence risk by 68%. Both saw unusual options activity, with bearish sentiment.